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Background: Tourette syndrome (TS) and chronic tic disorder (CTD) affect 1–2% of children and young people, but
the most effective treatment is unclear. To establish the current evidence base, we conducted a systematic review of
interventions for children and young people. Methods: Databases were searched from inception to 1 October 2014
for placebo-controlled trials of pharmacological, behavioural, physical or alternative interventions for tics in children
and young people with TS or CTD. Certainty in the evidence was assessed with the GRADE approach. Results: Forty
trials were included [pharmacological (32), behavioural (5), physical (2), dietary (1)]. For tics/global score there was
evidence favouring the intervention from four trials of a2-adrenergic receptor agonists [clonidine and guanfacine,
standardised mean difference (SMD) = 0.71; 95% CI 1.03, 0.40; N = 164] and two trials of habit reversal training
(HRT)/comprehensive behavioural intervention (CBIT) (SMD = 0.64; 95% CI 0.99, 0.29; N = 133). Certainty in
the effect estimates was moderate. A post hoc analysis combining oral clonidine/guanfacine trials with a clonidine
patch trial continued to demonstrate benefit (SMD = 0.54; 95% CI 0.92, 0.16), but statistical heterogeneity was
high. Evidence from four trials suggested that antipsychotic drugs improved tic scores (SMD = 0.74; 95% CI 1.08,
0.40; N = 76), but certainty in the effect estimate was low. The evidence for other interventions was categorised as
low or very low quality, or showed no conclusive benefit. Conclusions: When medication is considered appropriate
for the treatment of tics, the balance of clinical benefits to harm favours a2-adrenergic receptor agonists (clonidine
and guanfacine) as first-line agents. Antipsychotics are likely to be useful but carry the risk of harm and so should be
reserved for when a2-adrenergic receptor agonists are either ineffective or poorly tolerated. There is evidence that
HRT/CBIT is effective, but there is no evidence for HRT/CBIT alone relative to combining medication and HRT/CBIT.
There is currently no evidence to suggest that the physical and dietary interventions reviewed are sufficiently effective
and safe to be considered as treatments. Keywords: Paediatrics; Tourette syndrome; therapy; tics.
Introduction
Tourette syndrome (TS) and chronic tic disorder
(CTD), characterised by the presence of combined or
singular motor and phonic tics, have their onset in
childhood, typically around the age of 6 or 7 years (Jin
et al., 2005; Leckman et al., 1998) with tics at their
worst between the ages of 8 and 12 years (Leckman
et al., 1998). The prevalence in children has been
estimated as 0.4%–0.7% (Jin et al., 2005; Khalifa &
von Knorring, 2005; Kraft et al., 2012; Scharf, Miller,
Mathews, & Ben-Shlomo, 2012) for TS and 0.6%–
1.3% (Khalifa & von Knorring, 2005; Kraft et al.,
2012; Scharf, Miller, Mathews, & Ben-Shlomo, 2012)
for CTD (1% prevalence overall). In general, tics wane
in severity in late adolescence and early adult life
(Burd et al., 2001; Kraft et al., 2012; Leckman et al.,
1998), and in adulthood prevalence is lower (Sch-
lander, Schwarz, Rothenberger, & Roessner, 2011).
TS is frequently comorbid with other psychiatric
conditions including attention-deficit hyperactivity
disorder (ADHD; 60%), anxiety disorder (40%), obses-
sive compulsive disorder/obsessive compulsive
behaviours (OCD/OCB; 30%) and autism spectrum
disorder (ASD; 20%) (Robertson, 2015). Carers of
children with TS experience considerable burden and
risk of psychological morbidity (Cooper, Robertson, &
Livingston, 2003) and children with tic disorders
experience high rates of social (Kraft et al., 2012;
Wadman, Tischler, & Jackson, 2013), emotional
(Kraft et al., 2012; Robertson, Banerjee, Eapen, &
Fox-Hiley, 2002) and educational (Debes, Hjalgrim, &
Skov, 2010) impairment, and experience a lower
quality of life (Eddy et al., 2011).
Considering the nature of tic-related impairments
and implications for future life, knowledge of the best
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treatment options for TS in children is clinically
important. Detection and treatment of the psychi-
atric comorbidities which occur in the majority of
children with tics/TS may also be a clinical priority.
However, in many children, attempting to reduce the
severity, frequency, intensity and impact of tics is a
significant therapeutic target, and children and
parents report the importance of tic reduction
(Cuenca et al., 2015). Current practice varies
between countries but, following a course of psy-
choeducation (Robertson, 1989), where further
treatment is indicated, the most widespread mode
of treatment is pharmacotherapy. Commonly used
medications are antipsychotics, such as risperidone
and aripiprazole, or the a2-adrenergic receptor ago-
nists clonidine and guanfacine (Debes, Hjalgrim, &
Skov, 2009; Rickards, Cavanna, & Worrall, 2012).
Behavioural therapies, such as habit reversal train-
ing (HRT) and exposure and response prevention
(ERP), are used less often (Verdellen, van de Griendt,
Hartmann, Murphy, & ESSTS Guidelines Group).
This is often due to a lack of availability, financial
constraints or both. Physical treatments such as
repetitive transcranial magnetic stimulation (rTMS)
and, in adults, deep brain stimulation (DBS) (Muller-
Vahl et al., 2011; Steeves et al., 2012), have been
used with some success and reported in small case
series, although it is acknowledged that adequately
powered randomised trials are necessary. Alterna-
tive treatments such as fish oils, dietary supple-
ments, chiropody, yoga, acupuncture and antibiotics
(Debes et al., 2009; Kompoliti, Fan, & Leurgans,
2009; Woods, Conelea, & Himle, 2010) have also
been used for tics, but the rationale for their use and
efficacy of these treatments is unclear.
Comprehensive systematic reviews and meta-ana-
lyses of treatments for tics in children and young
people with TS and CTD are lacking. Although there
have been systematic reviews considering separately
pharmacological (Waldon, Hill, Termine, Balottin, &
Cavanna, 2013) and behavioural (Dutta & Cavanna,
2013; Wile & Pringsheim, 2013) interventions and a
number of narrative reviews underpinning clinical
guidelines (Muller-Vahl et al., 2011; Pringsheim
et al., 2012; Roessner et al., 2011; Steeves et al.,
2012; Verdellen, van Griendt, Hartmann, & Murphy,
2011), none have made an overall assessment of the
evidence for all types of treatment and attempted to
estimate the magnitude of benefits and harms and
robustly assess the quality of the evidence. A num-
ber of reviews (McGuire et al., 2014; Weisman,
Qureshi, Leckman, Scahill, & Bloch, 2013) have
combined the effects of treatment in children and
adult studies. This is unsatisfactory given that we
know that children and adults can differ in impor-
tant ways both in terms of the efficacy of treatments
(Thapar, Collishaw, Pine, & Thapar, 2012) and
susceptibility to adverse effects (NCCMH, 2013). A
further justification for this review is the lack of
systematic evidence-based clinical guidance for the
treatment of tics in children and young people. In the
United Kingdom, the National Institute of Health and
Care Excellence (NICE) has produced Clinical Guide-
lines for a range of childhood mental health condi-
tions, but so far it has not produced a guideline for
the management of young people with Tourette
syndrome despite the prevalence and impairment
associated with the condition. As a result, practi-
tioners are left to draw clinical inferences from a
small set of narrative and systematic reviews that
typically focus on separate modalities of treatment,
apply different standards of evidence and include
different populations of patients. The current review
aimed to improve upon past studies and establish
the magnitude of both benefits and harms associ-
ated with pharmacological, behavioural, physical
and alternative treatments for tics in children
(aged < 18 years) with a clinical diagnosis of TS or
CTD, when compared with a control group.
Methods
We partially updated an evidence synthesis conducted for the
NIHR Health Technology Assessment programme (Grant Ref:
10/142/01). Study eligibility criteria and the analysis plan
(including intervention classification scheme)were agreed by all
authors before data extraction began (Hollis et al., 2016). The
original review protocol was registered online with the Interna-
tional ProspectiveRegister of SystematicReviews inMarch2012
(Registration number: CRD42012002059) and can be accessed
at: http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42012002059. We followed the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA)
for performing and presenting the present review.
Data sources
Twenty-one databases covering medical/health (e.g. Medline,
CENTRAL, PsycINFO), education (e.g. ERIC), social care (e.g.
Social Services Abstracts) and grey literature (e.g. Health
Management Information Consortium) topics were searched
for studies in any language. Searches were conducted from
database inception to 1st January 2013 and updated in
October 2014. The search strategy included key words (tic or
tics or tourette$) and relevant subject headings (see Support-
ing Information for more information about the databases and
search strategy). Citations were screened by one reviewer (MP)
and hard copies of potentially relevant studies were obtained.
The list of both included and excluded studies were screened
by all authors and disagreements about eligibility were
discussed.
Eligibility criteria
Inclusion and exclusion criteria were formulated using the
PICO framework:
Patient/population. Aged <18 years old with a clinical
diagnosis of TS or CTD. Those with a transient tic disorder
(duration less than 12 months) were excluded. Studies where
the upper age included 18 year olds were allowed given that all
of these had a mean of between 10 and 14 years old.
Intervention. Pharmacological interventions1 (including anti-
psychotic drugs, clonidine, tetrabenazine, fluoxetine, clonazepam)
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and dietary interventions (including zinc, omega 3 fatty acids,
caffeine) used for the treatment of tics, or psychological/
behavioural and psychosocial interventions [including habit
reversal training (HRT), comprehensive behavioural intervention
for tics (CBIT), ERP, counselling and supportive psychotherapy,
family interventions, psychoeducation, relaxation training,
self-hypnosis, cognitive behavioural therapy and exercise) or
other physical interventions (including neuro-therapeutic inter-
ventions, such as transcranial magnetic stimulation, and other
physical interventions, such as acupuncture and botulinum
toxin injection) used for any reason.
Comparison. Placebo, treatment as usual or other mini-
mally active control. Head-to-head studies were excluded.
Outcome. Tic severity/frequency, or if not available, global
scores (including tic and impairment subscales) or motor tic
score.
Only randomised controlled trials (RCTs) or controlled
before–after studies were eligible. For some interventions, only
studies in mixed samples of children and adults were identi-
fied. Initially, authors were contacted and, where data from a
subgroup of children were available, these were included in the
review. Where subgroup data were not available, mixed studies
in children and adults were used as evidence. Decisions about
eligibility and classification of interventions were agreed by all
authors before data were extracted. With regard to clonidine, it
was decided that patches should be analysed separately from
oral clonidine as there was a high risk of heterogeneity between
these trials. However, we also conducted a post hoc analysis by
combining data from trials of oral clonidine with clonidine
patch trial data.
Data extraction and synthesis
Data were extracted by one reviewer and checked by a second
reviewer using a prepiloted Excel-based form. Where numer-
ous scales were reported, priority was given to the Yale Global
Tic Severity Scale (YGTSS) (Leckman et al., 1989) since this
was the most commonly reported scale and is currently in
common use. The Cochrane risk of bias tool was used to assess
risk of bias in included studies (Higgins & Green, 2011).
Additionally, for cross-over trials, the adequacy of the wash-
out period between treatments was considered to inform the
risk of bias assessment. The overall risk of bias for each study
was assessed on the basis of whether any source of bias was
likely to have had a significant impact on the findings (not
simply based on a count of the number of sources of bias). The
GRADE approach was used to assess certainty in the effect
estimates (quality of evidence) for each outcome (Guyatt,
Oxman, Schunemann, Tugwell, & Knottnerus, 2011) by one
author (MP) and confirmed by CW. Any disagreements were
discussed with other authors and consensus reached. The
GRADE approach is a structured method that takes into
consideration five separate factors: risk of bias; inconsistency
(defined as important heterogeneity with an I2 value that was
statistically significant and greater than 50%); indirectness of
the population, intervention, control or outcomes; imprecision
(number of participants less than the optimum information
size, assumed to be 300 events across dichotomous outcomes
and total number of participants of 400 across continuous
outcomes); and publication bias. Certainty in the effect
estimates was categorised as ‘high’ (very certain that the true
effect lies close to that of the estimate of the effect); ‘moderate’
(moderately certain in the effect estimate and the true effect is
likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different); ‘low’ (certainty in
the effect estimate is limited and the true effect may be
substantially different from the estimate of the effect); or ‘very
low’ (very little certainty in the effect estimate and the true
effect is likely to be substantially different from the estimate of
effect) (Balshem et al., 2011). Using the GRADE approach,
evidence from RCTs is initially classed as ‘high’, but may be
rated down one or two levels on the basis of any of the five
factors listed above.
Following the approach outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins & Green,
2011), we combined data from two or more individual trials
using the computer program Review Manager (RevMan, ver-
sion 5.3.; The Nordic Cochrane Centre, The Cochrane Colla-
boration 2014, Copenhagen, Denmark) using a random-effects
model. For outcomes measuring benefit of treatment, the
standardised mean difference (SMD) was used as the effect
size, calculated as the difference in mean change scores
divided by the pooled standard deviation of the change scores.
Hedges’ g correction for small sample size was applied auto-
matically by RevMan. The SMD was standardised so that a
negative effect size indicated that that the outcome favoured
the intervention relative to the control. For trials where
appropriate data were not directly reported, p values for the
net effect, if available, were used to calculate the SMD and
corresponding standard error (SE). In order to estimate the
precision of within-group changes where only baseline and
post-treatment means and standard deviation (SD) were
reported, a correlation coefficient of 0.6 was assumed (median
score found in studies reporting baseline, post-treatment and
change scores where correlation coefficient could be deter-
mined). For cross-over studies, data were analysed as a
comparison between post-treatment measures. Dichotomous
data from adverse effect outcomes were expressed as a risk
ratio (RR) and 95% CI.
Results
After removal of duplicate records, the search iden-
tified 6,345 citations and, of these, 223 were
obtained for full-text screening (Figure 1). Forty
trials in children or mixed studies (where children
studies were not available for a particular interven-
tion), published from 1987 to 2013 met eligibility
criteria (a list of all excluded studies is available from
the authors on request). Types of interventions and
number of trials are shown in Table 1. Of the 40
included trials, 32 were of pharmacological inter-
ventions, 5 of behavioural interventions, 2 of phys-
ical interventions and 1 of a dietary intervention.
The characteristics of included trials are shown in
Table 2 (pharmacological and dietary interventions)
and Table 3 (behavioural and physical interven-
tions). All interventions were given to participants
with TS or CTD and aimed at tics or comorbid
conditions (i.e. ADHD, OCD or ODD and incorporat-
ing a measure of tic frequency/severity as an
outcome). Of the 40 included trials, four included
mixed samples (children and adults); one study each
of topiramate (Jankovic, Jimenez-Shahed, & Brown,
2010), IV immunoglobulin (Hoekstra, Minderaa, &
Kallenberg, 2004), Botulinum toxin (Marras,
Andrews, Sime, & Lang, 2001) and clonidine (Leck-
man et al., 1991). The Leckman et al. study was not
the only trial of clonidine and therefore could have
been excluded based on our eligibility criteria. How-
ever, the mean age was approximately 15 years and
only 23% of the sample were 18 years or older.
Therefore, it was decided to include this trial.
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It should be noted that all trials that were excluded
on the basis of age had a mean age above 18, with
the majority of participants being adults.
The evidence for selected benefits and important
harms associated with each intervention, and the
GRADE assessment of certainty in the effect esti-
mates are shown in Table 4. A graphical display of
the main outcome (benefit) for each intervention
subgrouped by GRADE category can be found in
Figure 2. Outcomes were mostly graded as low or
very low, but for a small number of interventions,
there was moderate certainty in the evidence (no
evidence with high certainty was identified).
Pharmacological interventions
Interventions with moderate certainty in the esti-
mates of effect. There was evidence from pooling
the results of four trials (total sample size, N = 164)
that a adrenergic receptor agonists (clonidine and
guanfacine) had a medium-sized benefit on tic/
global score (SMD = 0.74; 95% CI 1.06, 0.42;
I2 = 0%; heterogeneity p = 1.00). There was evidence
from one large trial (N = 437) that failed to show a
benefit of clonidine patch on tics (SMD = 0.10; 95%
CI 0.32, 0.12). A post hoc analysis combining oral
clonidine/guanfacine and clonidine patch produced
a medium-sized benefit on tic/global score (SMD =
0.54; 95% CI 0.92, 0.16), but statistical
heterogeneity was high (I2 = 63%; heterogeneity
p = .03). Based on one relatively large trial
(N = 145) there was evidence that atomoxetine had
a positive effect on tics, but the estimate of effect was
imprecise (SMD = 0.32; 95% CI 0.65 to 0.01).
Interventions with low or very low certainty in the
estimates of effect. There was evidence from
pooling the results of four trials that antipsychotic
drugs improved tics (SMD = 0.78; 95% CI 1.13,
0.43; N = 136). There was no evidence of important
differences between specific antipsychotic drugs
in the size of the effect (I2 = 0%; heterogeneity
p = .74): aripiprazole (SMD = 0.62), haloperidol
(SMD = 0.50), pimozide (SMD = 0.81), risperidone
(SMD = 1.18) and ziprasidone (SMD = 0.74). There
was evidence from one trial of each drug that meto-
clopramide (SMD = 1.43; 95% CI 2.28, 0.59;
N = 27), desipramine (SMD = 0.96; 95% CI 1.63,
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(n = 8,295)
Records after duplicates removed
(n = 7,277)
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (the number of studies is shown in
parentheses; numbers marked with an asterisk include at least one mixed study of children/young people and adults)
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0.29; N = 39) and topiramate (SMD = 0.88; 95%
CI 1.68, 0.08; N = 27) improved tics. There was
some evidence from one trial of each drug that
selegiline (SMD = 0.72; 95% CI 1.45, 0.02;
N = 15) and pergolide (SMD = 0.59; 95% CI 1.21,
0.02; N = 51) may improve tics. The evidence from
one trial of each drug was inconclusive regarding the
benefit of levetiracetam (SMD = 0.23; 95% CI
0.85, 0.39; N = 40) and pramipexole (SMD = 0.00;
95% CI 0.53, 0.53; N = 62). For other medications,
evidence from one trial for each drug was inconclu-
sive: baclofen (SMD = 0.54; 95% CI 1.50, 0.42;
N = 9), fluoxetine (SMD = 0.90; 95% CI 2.15, 0.34;
N = 11) and ondansetron (SMD = 0.38; 95% CI
1.42, 0.66; N = 15). For CNS stimulants, the impor-
tant finding from four trials was that they did not
appear to worsen tics (SMD = 0.17; 95% CI 0.45,
0.11; N = 161).
Harms associated with treatment. Given the
relatively small sample sizes and small number of
trials for each drug, we focus here on any evidence
of increased overall adverse effects and any serious
adverse effects reported. In one trial of oral
clonidine, there was an increased risk of adverse
effects (RR = 1.87; 95% CI 1.24, 2.81). With regard
to antipsychotic drugs, there was evidence that
only haloperidol increased extrapyramidal symp-
toms when compared to placebo (SMD = 0.51;
95% CI 0.11, 0.90; N = 22). In one trial of
desipramine (TCA antidepressant), there was an
increased risk of adverse effects (RR = 1.73; 95%
CI 1.14, 2.64).
Dietary interventions
In one small trial (N = 33) of omega 3 fatty acids, the
evidence was inconclusive regarding the effect on
tics (SMD = 0.24; 95% CI 0.93, 0.45). Certainty in
the effect estimate was low.
Behavioural interventions
Interventions with moderate certainty in the esti-
mates of effect. When the results of two trials
(N = 133) were pooled, there was evidence of a
medium-sized effect in improving tics in favour of
behavioural therapy (HRT/CBIT) when compared
to waitlist/supportive psychotherapy (SMD = 0.64;
95% CI 0.99, 0.29; I2 = 0%; heterogeneity p = .94).
Interventions with low or very low certainty in the
estimates of effect. Evidence for other behavioural
interventions, from one trial each, was inconclusive:
anger control training (SMD = 0.58; 95% CI 1.37,
0.20; N = 26), parent training (SMD = 0.29; 95% CI
0.53, 1.12; N = 23) and relaxation training
(SMD = 0.61; 95% CI 1.76, 0.54; N = 16).
Physical interventions
Evidence from one trial for each intervention was
inconclusive as to the benefit of botulinum toxin
(SMD = 0.02; 95% CI 0.63, 0.67; N = 18) and IV
immunoglobulins (SMD = 0.51; 95% CI 1.25,
0.23; N = 29) on tics. Certainty in the effect esti-
mates was low. In the trial of IV immunoglobulins,
there was an increased risk of adverse effects
(RR = 3.48; 95% CI 1.49, 8.16). There was no
evidence for DBS or rTMS in children or in mixed
children and adult studies.
Table 1 Number of articles providing data for each interven-
tion, categorised by type of intervention
Intervention
Number of
studies
Pharmacological interventions
a2-adrenergic receptor agonists
Clonidine 4a
Clonidine patch 2
Guanfacine 2
Antihypertensive
Mecamylamine 1
Antidepressants (SSRI)
Fluoxetine 1
Antidepressants (TCA)
Desipramine 2
Antiemetics
Metoclopramide 1
Ondansetron 1
Anticonvulsants
Levetiracetam 1
Topiramate 1a
Antiparkinsonian agents
Selegiline 1
Antipsychotics
Aripiprazole 1
Haloperidol 1
Pimozide 1
Risperidone 1
Ziprasidone 1
CNS stimulants
Methylphenidate 3
Dopaminergic agents
Pergolide 2
Pramipexole 1
Muscle relaxants
Baclofen 1
Smoking cessation agents
Nicotine patch 1
Selective norepinephrine reuptake inhibitor
Atomoxetine 1
Dietary interventions
Omega 3 fatty acids 1
Behavioural interventions
Anger control training 1
HRT/CBIT 2
Parent training 1
Relaxation training 1
Physical interventions
Botulinum toxin 1a
IV immunoglobulin 1a
Total number of studies 40
aMixed sample of children/young people and adults.
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Discussion
Habit reversal training (HRT) and ERP are recom-
mended as first-line interventions for children and
young people with TS or CTD (Verdellen et al., 2011).
Our results broadly support this recommendation,
with evidence that behavioural interventions (CBIT/
HRT) have a similar magnitude of effect to pharma-
cological interventions and the profile of adverse
effects is more favourable. However, for many young
people with tics and Tourette syndrome, pharmaco-
logical treatments may be considered either because
of the limited availability and access to behavioural
interventions, or lack of treatment response. Despite
the widespread use of antipsychotic medications for
the treatment of tics, certainty in the effect estimates
(quality of the body of evidence) was low for their
overall efficacy in children and young people. Given
that it is well established that the side-effect profiles
differ between antipsychotic drugs, we considered
the antipsychotics individually. The evidence for
risperidone came from one small study and,
although this study was determined to have a low
risk of bias, the true magnitude of effect is uncertain.
For pimozide and haloperidol, evidence was from the
same small cross-over study with uncertain validity,
and similarly, for ziprasidone, only a single small
study with uncertain validity contributed evidence.
Aripiprazole compared favourably to placebo in our
review and in head-to-head comparisons with other
antipsychotics (haloperidol and tiapride) (Liu et al.,
2011; Yoo et al., 2011). Against placebo, there was
no increased risk of adverse events, including
extrapyramidal symptoms, but the trial (Yoo et al.,
2013) included only 60 participants in the safety
evaluation and therefore may not have sufficient
statistical power to detect treatment-related adverse
effects. These findings suggest that aripiprazole may
be a useful antipsychotic agent for the treatment of
tics, with a similar magnitude of effect to that of
other antipsychotic agents. Olanzapine has only
been assessed in a head-to-head study (vs. haloperi-
dol) (Ji, Li, Li, & Guo, 2005), that provided low-
quality evidence for its comparative efficacy. In light
of the current low-quality evidence of efficacy and
potential for adverse effects, there appears to be a
need for further research into the use of antipsy-
chotics for children and young people with TS.
The review found moderate certainty in the esti-
mate of effect for the use of the a2-adrenergic
receptor agonists clonidine and guanfacine (based
on four studies with low risk of bias). When the
results were pooled, there was a medium-sized
benefit (SMD = 0.74). We took an a priori decision
to separate trials of oral clonidine from patches
because the group felt there was a high risk of
heterogeneity between trials of oral clonidine and
patches. A post hoc analysis combining these trials
continued to demonstrate benefit (SMD = 0.54) but
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Table 4 Results of trials assessing interventions for Tourette syndrome
Intervention Study Age
Benefit (effect size
and 95% CI)
Overall adverse effects
(AEs) or serious
AEs (effect size
and 95% CI)a
Certainty
in the effect
estimate for
benefit
(GRADE)b
a2-adrenergic receptor agonists
Clonidine or
guanfacine
Cummings et al. (2002) CYP Tics/global score (k = 4):
SMD = 0.74
(1.06, 0.42)
Clonidine
AE (k = 1): RR = 1.87
(1.24, 2.81)
Guanfacine
AE (k = 2):
No differences
between
groups reported
Moderatec
Kurlan et al. (2002) CYP
Leckman et al. (1991) Mixed
Scahill et al. (2001) CYP
Clonidine patch Du et al. (2008) CYP Tics (k = 1): SMD = 0.10
(0.32, 0.12)
AE (k = 1): RR = 0.34
(0.13, 0.89)
Moderated
Zhong et al. (2007) CYP
Antihypertensives
Mecamylamine Silver, Shytle,
Sheehan et al. (2001)
CYP Tics (k = 1):
Comparative effect NR
– Lowc,d
Antidepressants (SSRI)
Fluoxetine Kurlan et al. (2002) CYP Motor tics (k = 1):
SMD = 0.90
(2.15, 0.34)
– Very lowc,d
Antidepressants (TCA)
Desipramine Singer et al. (1995) CYP Tics (k = 1): SMD = 0.96
(1.63, 0.29)
AE (k = 1): RR = 1.73
(1.14, 2.64)
Lowc
Spencer et al. (2002) CYP
Antiemetics
Metoclopramide Nicolson et al. (2005) CYP Tics (k = 1): SMD = 1.43
(2.28, 0.59)
– Lowc,d
Ondansetron Toran et al. (2005) CYP Tics (k = 1): SMD = 0.38
(1.42, 0.66)
– Very lowc,d
Anticonvulsants
Levetiracetam Smith-Hicks et al. (2007) CYP Tics (k = 1): SMD = 0.23
(0.85, 0.39)
– Lowc,d
Topiramate Jankovic et al. (2010) Mixed Tics (k = 1): SMD = 0.88
(1.68, 0.08)
AE: RR = 0.79
(0.56, 1.11)
Lowc
Antiparkinsonian agents
Selegiline Feigin et al. (1996) CYP Global (k = 1): SMD = 0.72
(1.45, 0.02)
– Lowc,d
Antipsychotics
Any Sallee et al. (1997)
Sallee et al. (2000)
Scahill et al. (2003)
Yoo et al. (2013)
CYP Tics (k = 4): SMD = 0.78
(1.13, 0.43)
– Lowc,d
Aripiprazole Yoo et al. (2013) CYP Tics (k = 1): SMD = 0.62
(1.14, 0.11)
AE: RR = 1.05
(0.77, 1.43)
EPS: SMD = 0.28
(0.24, 0.79)
Moderatec
Haloperidol Sallee et al. (1997) CYP Tics (k = 1): SMD = 0.50
(0.89, 0.10)
EPS: SMD = 0.51
(0.11, 0.90)
Lowc,d
Pimozide Sallee et al. (1997) CYP Tics (k = 1): SMD = 0.81
(1.24, 0.38)
EPS: SMD = 0.20
(0.18, 0.58)
Lowc,d
Risperidone Scahill et al. (2003) CYP Tics (k = 1): SMD = 1.18
(2.02, 0.34)
– Lowc
Ziprasidone Sallee et al. (2000) CYP Tics (k = 1): SMD = 0.78
(1.54, 0.06)
AE: RR = 1.68
(1.05, 2.70)
Lowc,d
CNS stimulants
Methylphenidate Gadow et al. (1992) CYP Motor tics (k = 3):
SMD = 0.03
(0.20, 0.15)
– Lowc,d
Gadow et al. (2007) CYP
Kurlan et al. (2002) CYP
Dopamine agents
Pergolide Gilbert et al. (2000) CYP Tics (k = 1): SMD = 0.59
(1.21, 0.02)
AE (k = 2): SMD = 0.05
(0.49, 0.38)
QT interval (k = 1):
MD 13.50
(4.29, 31.29)
Lowc
Gilbert et al. (2003) CYP
Pramipexole Kurlan et al. (2012) CYP Tics (k = 1): SMD = 0.00
(0.53, 0.53)
AE: RR = 1.62
(0.70, 3.76)
Lowc,d
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due to chance, making the pooled estimate difficult
to interpret. We found that clonidine was associated
with increased rates of sedation, but for guanfacine,
no increased rates of side effects were reported.
Alpha 2-adrenergic receptor agonists appear to be
useful for the treatment of children with tic disor-
ders. Given their efficacy and relatively benign
adverse effect profile, these agents may be a good
first-line pharmacological treatment for tics in
children and young people. A pilot study (double-
blind RCT) is currently being conducted to determine
the efficacy and safety of extended-release guan-
facine in children with tic disorders (NCT01547000)
and may provide further evidence for the efficacy and
safety of this drug. Guanfacine, previously licensed
in the United States is now being reviewed for
licensing (marketing authorisation) in the United
Kingdom (European Union). In our review, an
important finding for clinical practice was that
stimulants used to treat comorbid ADHD and TS/
tics did not appear to worsen tics. This finding
supports other recent systematic reviews and meta-
analyses which have found no increased risk of new
onset tics, or tic worsening with stimulant medica-
tion compared to placebo (Cohen et al., 2015; Pring-
sheim & Steeves, 2011). However, despite there
being no overall group effect of stimulants on tics,
clinical reports indicate that tics may be exacerbated
in certain individuals at higher stimulant doses, with
tic worsening reversible by stimulant dose reduction
(Castellanos, 1997).
There was no controlled evidence for the use of
DBS or repetitive transcranial magnetic stimulation
(rTMS) in children. These physical treatments are
Table 4 (continued)
Intervention Study Age
Benefit (effect size
and 95% CI)
Overall adverse effects
(AEs) or serious
AEs (effect size
and 95% CI)a
Certainty
in the effect
estimate for
benefit
(GRADE)b
Muscle relaxants
Baclofen Singer et al. (2001) CYP Tics (k = 1): SMD = 0.54
(1.50, 0.42)
– Very lowc,d
Smoking cessation agents
Nicotine patch Howson et al. (2004) CYP Motor tic score (k = 2):
SMD = 0.03
(0.49, 0.43)
– Lowc,d
Silver, Shytle,
Philipp, et al. (2001)
CYP
Selective norepinephrine reuptake inhibitor
Atomoxetine Allen et al. (2005) CYP Tics (k = 1): SMD = 0.32
(0.65, 0.01)
– Moderatec
Dietary interventions
Omega 3
fatty acids
Gabbay et al. (2012) CYP Tics (k = 1): SMD = 0.24
(0.93, 0.45)
AE: ‘no significant
treatment
differences’
were reported
Lowc,d
Behavioural interventions
Anger control
training
Sukhodolsky
et al. (2009)
CYP Tics (k = 1): SMD = 0.58
(1.37, 0.20)
– Lowc,d
HRT/CBIT Azrin and
Peterson (1990)
CYP Tics (k = 2): SMD = 0.64
(0.99, 0.29)
– Moderatec
Piacentini et al. (2010) CYP
Parent training Scahill et al. (2006) CYP Tics (k = 1): SMD = 0.29
(0.53, 1.12)
– Very lowc,d
Relaxation
training
Bergin et al. (1998) CYP Global (k = 1): SMD = 0.61
(1.76, 0.54)
– Very lowc,d
Physical interventions
Botulinum
toxin
Marras et al. (2001) Mixed Tics (k = 1): SMD = 0.02
(0.63, 0.67)
– Lowc,d
IV immunoglobulin Hoekstra et al. (2004) Mixed Tics (k = 1): SMD = 0.51
(1.25, 0.23)
AE: RR = 3.48
(1.49, 8.16)
Lowc,d
AE, adverse event; CYP, children and young people; EPS, extrapyramidal symptoms; k, number of studies; Mixed, mixed sample of
CYP and adults; RR, relative risk; TS, Tourette syndrome; SMD, standardised mean difference.
aSpecific adverse events, other than those considered to be serious, are not reported here.
bGrading of Recommendations Assessment, Development and Evaluation Working Group grades of evidence are as follows.
High = further research is very unlikely to change our certainty in the effect estimate; moderate = further research is likely to have
an important impact on our certainty in the effect estimate and may change the estimate; low = further research is very likely to have
an important impact on our certainty in the effect estimate and is likely to change the estimate; and very low = we are very uncertain
about the estimate.
cSample size does not reach optimal information size (outcome downgraded by one or two levels).
dOverall, studies reporting this outcome were associated with high risk of bias (outcome downgraded by one or two levels).
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currently experimental (rTMS) or confined to use in
adults (DBS). Given the current lack of evidence of
efficacy and the safety risks involved, treatment of
paediatric populations appears inappropriate.
The review highlighted the lack of evidence for
alternative treatments that are in current use. Evi-
dence from studies of botulinum toxin and omega-3
fatty acids was graded as low quality. The only trial
of acupuncture in children with TS or CTD was a
head-to-head study against haloperidol (Xu, Ze,
Shu-zi, Da-Peng, & Yuan-zheng, 2003) and provided
very low-quality evidence. There was no evidence for
the use of dietary supplements, vitamins, yoga or
chiropody.
It should be noted that efficacy of behavioural
therapy was largely driven by the trial of CBIT
(Piacentini et al., 2010), which had a much bigger
sample size and slightly larger effect size
(SMD = 0.64, 95% CI 1.0, 0.29) than the trial
of HRT (Azrin & Peterson, 1990). Nevertheless,
despite evidence for the efficacy of behavioural
therapy and low risk of associated adverse events,
difficulties around access and financial constraints
may hinder the widespread use of behavioural
treatments. There was some indication that therapy
was effective with a reduced number of treatment
sessions (after 5 sessions, SMD = 0.48, 95% CI
0.83, 0.12) (Piacentini et al., 2010) but the longer
term benefits of differing treatment lengths are
unclear. A small study comparing CBIT delivered
via video conference compared to face-to-face ther-
apy has shown promise that this may be a useful
alternative mode of delivery for increasing availabil-
ity of behavioural therapy (Himle et al., 2012), but
further research would be needed to indicate whether
this is an effective alternative to face-to-face delivery.
In studies of behavioural therapy, patients receiving
medication for tics were included and so questions
remain around the relative benefits of behavioural
treatments alone and in combination with medica-
tions. Further research comparing behavioural ther-
apy with or without medication together with an
analysis of the moderating effects of tic severity and
comorbid conditions would contribute important
information to inform treatment practice.
The main limitation of this review was the paucity
of available evidence and, to an extent, the review
strategy. The small number and sample size of
studies for any given intervention limited their
interpretation and there is still uncertainty around
which treatments are best and the magnitude of
their effects. Many interventions had no, or only very
low quality, evidence and no conclusions can be
drawn about their efficacy. The majority of studies
compared short-term post-treatment effects, and the
longer term efficacy of interventions is uncertain.
Most studies did not report changes in comorbid
conditions and focussed on changes in tics and there
is also uncertainty around the effect of interventions
on comorbid symptoms and TS-related impairments.
There is a need to formally evaluate the impact of
psychoeducation, as this typically incorporates
information on tics and comorbidities, and helps
families and clinicians establish where the most
significant impairment lies. The clinical significance
of changes in tic scores, that is, the minimum
clinically important difference (MCID) on commonly
used scale such as the YGTSS requires further study
Figure 2 Effect sizes for interventions in children and young people with Tourette syndrome categorised by GRADE assessment (CBIT,
comprehensive behavioural intervention for tics; HRT, habit reversal training; IVIG, intravenous immunoglobulin)
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and should be established a priori in future treat-
ment trials. Several studies have shown that
although tics may represent the most evident symp-
tom, the major impairment lies with one or more
psychiatric comorbidities (Bernard et al., 2009; Gor-
man et al., 2010). Treatment choices may differ
depending on the relative balance of impairment
associated with tics and comorbid symptoms, but
the evidence base for the treatment of comorbidities
with TS and CTD lies outside the scope of this review.
This is a limitation, as in clinical practice a priority
for improving function may be detection and treat-
ment of comorbidity. Rates of psychiatric comorbid-
ity are high in Tourette syndrome, and emerge early
in life, a recent large study reporting a life-time
prevalence of 86% (Hirschtritt et al., 2015). For
example, the presence of a significant anxiety disor-
der may contribute markedly to social and educa-
tional impairment in a child, although tics may be
the presenting difficulty. This clinical formulation
needs to be discussed with the family, and the
relative impact of symptoms examined. It may be
that in an individual clinical situation, a first treat-
ment step would be a trial of anxiety treatment,
which might in itself lead to reduction in tics, or
better tolerance of the same level of tics. These
concepts of hierarchical/step-wise treatments are
familiar to clinicians working with children with
mixed neurodevelopmental disorders, and further
research is needed to explore the effects of the
treatment of psychiatric comorbidity on tic severity
and impact. An innovative trial design called
Sequential, Multiple Assignment, Randomized Trial
(SMART), which is used for development of person-
alised treatments (Collins, Nahum-Shani, & Almirall,
2014) may be particularly appropriate for the eval-
uation of step-wise treatment approaches for tics
and Tourette syndrome. Finally, studies reviewed
indicated a high degree of interindividual variability
in response, indicating that, in practice, it may be
difficult to predict which treatment an individual will
respond to best.
The long-term side effects associated with inter-
ventions, particularly with pharmacological
treatments, are unclear. This review only synthe-
sised short-term controlled studies and only consid-
ered safety outcomes in studies of TS or CTD
patients. A review of use across other disorders in
children and young people including longer term
uncontrolled studies would give a much more com-
prehensive assessment of the evidence for adverse
effects but this was outside the scope of the review.
However, many of the important side effects were
identified by our work and, by restricting the review
to controlled studies, we could obtain more reliable
estimates of the proportion of patients likely to have
experienced adverse events. Another limitation intro-
duced by the restriction to placebo-controlled stud-
ies was that interventions investigated with other
study designs were not assessed in the review.
However, the poor quality of evidence provided by
uncontrolled studies limits their interpretation and
they were unlikely to have added value to the review.
Despite these limitations, the present systematic
review has provided a strong foundation to build on,
including registration of the review protocol, robust
methods for identifying the evidence, an assessment
of risk of bias and application of the GRADE
approach to rating certainty in the estimates of
effect. Nevertheless, considering the small amount
of available evidence, continued research and review
of the evidence for all types of treatments is needed,
in particular, the combination of pharmacological
and behavioural interventions and the use of tech-
nology to increase access to behavioural interven-
tions.
Conclusion
In summary, the balance of clinical benefits to harm
favours a2-adrenergic receptor agonists (e.g. cloni-
dine, guanfacine) as first-line drug treatments for
tics in children and young people. Antipsychotics
(e.g. risperidone, aripiprazole) may be as effective as
a2-adrenergic receptor agonists but considering the
low quality of evidence and adverse effect profile,
they may be reserved for treatment of tics when a2-
adrenergic receptor agonists are either ineffective or
poorly tolerated. There is evidence that HRT/CBIT is
an effective treatment for tics in children and young
people with TS. However, there is currently no
evidence available regarding the relative benefits of
HRT/CBIT alone compared to combining medication
and HRT/CBIT. In clinical practice, young people
and their parents may prefer to start a behavioural
intervention before considering medication (Cuenca
et al., 2015). Given the broadly similar efficacy of
behavioural and pharmacological interventions it
would seem reasonable to give significant weighting
to these patient preferences. However, it should be
remembered that we know very little about the
relative efficacy of behavioural interventions alone
or in combination with medication. Importantly, our
review showed that stimulant medication used to
treat comorbid ADHD/TS does not appear to exac-
erbate tics. There is currently no evidence to suggest
that the physical/alternative interventions reviewed
(DBS, rTMS, botulinum toxin, IV immunoglobulins,
omega 3 fatty acids and acupuncture) are suffi-
ciently effective and safe to be considered as treat-
ments for tics in children and young people with TS.
Given that young people and their parents may seek
alternative treatments, it is important to emphasise
that their use is not supported by any robust
evidence.
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Key points
Key practitioner message
• Tourette syndrome (TS) and chronic tic disorder affect 1%–2% of children and young people and cause
significant psychosocial impairment. However, there is a lack of evidence-based clinical guidance for
practitioners.
• Behavioural intervention for tics (HRT/CBIT) demonstrates similar effectiveness to medication, and a more
favourable adverse effect profile, which suggests that it should be offered as a first-line intervention for young
people with tics.
• When medication is considered appropriate, the balance of clinical benefits to harm may favour a 2 agonists
(i.e. clonidine and guanfacine).
• Antipsychotics are likely to be useful but may be reserved for when noradrenergic agents are either ineffective
or poorly tolerated.
• Stimulant medication used to treat comorbid ADHD/TS does not appear to exacerbate tics. However, if tic
worsening does occur it is more likely with higher doses and reversible with stimulant dose reduction.
• There is currently no evidence regarding the relative benefits of HRT/CBIT alone compared to benefits of
combining medication and behavioural intervention.
• There is currently no evidence to suggest that the physical/alternative interventions reviewed are sufficiently
effective and safe to be considered as treatments for tics in children and young people with TS.
Areas for future research
• Future research should focus on the development and evaluation of digital technologies that can increase
access to behavioural interventions.
• The cost-effectiveness of different treatment interventions for tics needs to be assessed.
• RCTs assessing the relative benefits of HRT/CBIT alone compared to combining medication and HRT/CBIT are
needed.
• Innovative trial designs such as Sequential, Multiple Assignment, Randomized Trial (SMART) may be
particularly appropriate for the evaluation of step-wise treatment approaches for tics and Tourette syndrome.
• The safety and efficacy of the physical/alternative interventions reviewed (DBS, rTMS, botulinum toxin, IV
immunoglobulins, omega 3 fatty acids and acupuncture) also need to be assessed.
• The moderating effects of age, tic severity, premonitory urges and common comorbidities (e.g. ADHD, OCD,
anxiety and depression) on treatment of tics needs to be assessed.
• The moderating effects of tics on treatment outcomes for common comorbid conditions (e.g. ADHD, OCD,
anxiety and depression) needs to be assessed.
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Note
1. Eligible if they were licensed for use in any
disorder in North America, Europe or Australasia.
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Tourette syndrome (TS) is a common neurodevelopmental condition affecting approximately 1% of children and
young people (c. 70,000 people age 7–17 years in England) which if untreated has a major adverse impact on mental
health, social functioning and quality of life. Despite the prevalence of TS in young people being greater than diabetes
and epilepsy, it remains a frequently misunderstood condition and its seriousness at a population level is typically
overlooked, as evidenced by the absence of evidence-based clinical guidelines. TS is characterised by persistent and
impairing motor and vocal tics which typically emerge in childhood, run a waxing and waning course and carry on
into adult life in about 30% of young people. Tics can be highly stigmatising, especially for teenagers, and often lead
to bullying, peer victimisation, social exclusion, depression and self-harm. TS is associated and frequently coexists
with other neurodevelopmental and mental health conditions including ADHD (60%), anxiety disorder (40%), OCD
(30%) and ASD (20%) which add to the complexity of clinical management. Evidence from this major systematic
review and meta-analysis shows that clinically effective treatments for tics in children and young people exist and
include medication (e.g. a2-noradrenergic agonists and antipsychotics) and behavioural interventions, including
exposure and response prevention, habit reversal training (HRT) and the comprehensive behavioural intervention for
tics programme which combines psychoeducation with HRT. The results of this review suggest that both medication
and behavioural interventions have similar efficacy (moderate effect size) in treating tics, with behavioural
interventions having a more favourable adverse effect profile. When considering medication, the more favourable
adverse effect profile of a2-noradrenergic agonists suggests that these agents should be offered before antipsychotics.
However, psychoeducation and behavioural interventions are generally the preferred treatment option, particularly
as first-line interventions, by young people and their parents. Despite demonstrated efficacy, access in most
healthcare systems to evidence-based behavioural interventions for tics is extremely poor. Therefore, given the
healthcare challenge of delivering behavioural interventions at scale with existing numbers of therapists and the
traditional model of face-to-face delivery there is a pressing need to develop and evaluate digitally delivered
interventions for young people with tics using a stepped-care model of therapist support.
